{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:55:44Z","timestamp":1790549744343,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41429-026-00942-y","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:02:41Z","timestamp":1783670561000},"page":"687-697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bortezomib exhibited bacteriostatic activity and pro-inflammatory effect against Mycoplasma pneumoniae"],"prefix":"10.1038","volume":"79","author":[{"given":"Zhikun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"942_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/CMR.17.4.697-728.2004","volume":"17","author":"KB Waites","year":"2004","unstructured":"Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17:697\u2013728.","journal-title":"Clin Microbiol Rev"},{"key":"942_CR2","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/jcm11102824","volume":"11","author":"L Tong","year":"2022","unstructured":"Tong L, Huang S, Zheng C, Zhang Y, Chen Z. Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management. J Clin Med. 2022;11:2824.","journal-title":"J Clin Med"},{"key":"942_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/jac\/dks457","volume":"68","author":"P Nicola","year":"2013","unstructured":"Nicola P, Susanna E. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother. 2013;68:506\u201311.","journal-title":"J Antimicrob Chemother"},{"key":"942_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10156-009-0021-4","volume":"16","author":"M Morozumi","year":"2010","unstructured":"Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010;16:78\u201386.","journal-title":"J Infect Chemother"},{"key":"942_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/986527","volume":"2014","author":"Q Ye","year":"2014","unstructured":"Ye Q, Xu XJ, Shao WX, Pan YX, Chen XJ. Mycoplasma pneumoniae infection in children is a risk factor for developing allergic diseases. Sci World J. 2014;2014:986527.","journal-title":"Sci World J"},{"key":"942_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2024.107072","volume":"197","author":"ZK Zhang","year":"2024","unstructured":"Zhang ZK, Shi DW, Dou HW, Wan RJ, Yuan Q, Tu P, Xin DL. Mycoplasma pneumoniae regulates the expression of GP130 in lung epithelial cells through apoptosis and TLR4\/ NF-\u03baB pathway during infection. Micro Pathogenesis. 2024;197:107072.","journal-title":"Micro Pathogenesis"},{"key":"942_CR7","first-page":"479","volume":"61","author":"Shin Ki","year":"2010","unstructured":"Ki Shin, Shen L, Park SJ, Jeong J, Ka Lee. Bis-(3-hydroxyphenyl) diselenide inhibits LPS-stimulated iNOS and COX-2 expression in RAW 264.7 macrophage cells through the NF-kappaB inactivation. J Pharm Pharm. 2010;61:479\u201386.","journal-title":"J Pharm Pharm"},{"key":"942_CR8","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1074\/jbc.M109.072694","volume":"285","author":"C Li","year":"2010","unstructured":"Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun S-Y. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent I\u03baB\u03b1 degradation. J Biol Chem. 2010;285:16096\u2013104.","journal-title":"J Biol Chem"},{"key":"942_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1088725","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Dou H, Tu P, Shi D, Wei R, Wan R, et al. Serum cytokine profiling reveals different immune response patterns during general and severe Mycoplasma pneumoniae pneumonia. Front Immunol. 2022;13:1088725.","journal-title":"Front Immunol"},{"key":"942_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-017-0101-y","volume":"11","author":"K Wang","year":"2017","unstructured":"Wang K, Gao M, Yang M, Meng F, Li D, Lu R, et al. Transcriptome analysis of bronchoalveolar lavage fluid from children with severe Mycoplasma pneumoniae pneumonia reveals novel gene expression and immunodeficiency. Hum Genomics. 2017;11:4.","journal-title":"Hum Genomics"},{"key":"942_CR11","first-page":"188","volume":"13","author":"YM Kang","year":"2011","unstructured":"Kang YM, Ding MJ, Han YL, Wang SF, Li H. Th1\/Th2 immune response in bronchoalveolar lavage fluid in children with severe Mycoplasma pneumoniae pneumonia. Zhongguo dang dai er ke za zhi = Chin J Contemp Pediatr. 2011;13:188\u201390.","journal-title":"Zhongguo dang dai er ke za zhi = Chin J Contemp Pediatr"},{"key":"942_CR12","doi-asserted-by":"publisher","first-page":"9439","DOI":"10.1128\/JVI.00533-10","volume":"84","author":"SE Dudek","year":"2010","unstructured":"Dudek SE, Luig C, Pauli E-K, Schubert U, Ludwig S. The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state. J Virol. 2010;84:9439\u201351.","journal-title":"J Virol"},{"key":"942_CR13","doi-asserted-by":"publisher","first-page":"12419","DOI":"10.1128\/JVI.01219-10","volume":"84","author":"X-Z Ma","year":"2010","unstructured":"Ma X-Z, Bartczak A, Zhang J, Khattar R, Chen L, Liu MF, et al. Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome. J Virol. 2010;84:12419\u201328.","journal-title":"J Virol"},{"key":"942_CR14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12250-019-00162-9","volume":"34","author":"S Liu","year":"2019","unstructured":"Liu S, Liu H, Zhang K, Li X, Duan Y, Wang Z, Wang T. Proteasome inhibitor PS-341 effectively blocks infection by the severe fever with thrombocytopenia syndrome virus. Virologica Sin. 2019;34:572\u201382.","journal-title":"Virologica Sin"},{"key":"942_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tox.2009.11.014","volume":"268","author":"C Lupfer","year":"2010","unstructured":"Lupfer C, Patton KM, Pastey MK. Treatment of Human Respiratory Syncytial Virus infected Balb\/c mice with the proteasome inhibitor bortezomib (Velcade\u00ae, PS-341) results in increased inflammation and mortality. Toxicology. 2010;268:25\u201330.","journal-title":"Toxicology"},{"key":"942_CR16","first-page":"2638","volume":"5","author":"BA Teicher","year":"1999","unstructured":"Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5:2638\u201345.","journal-title":"Clin Cancer Res"},{"key":"942_CR17","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.3892\/mmr.2016.5765","volume":"14","author":"J He","year":"2016","unstructured":"He J, Liu M, Ye Z, Tan T, Liu X, You X, et al. Insights into the pathogenesis of Mycoplasma pneumoniae. Mol Med Rep. 2016;14:4030\u20136.","journal-title":"Mol Med Rep"},{"key":"942_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/pathogens10020119","volume":"10","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, Li S, Zhu C, Zhou R, Leung PH. Mycoplasma pneumoniae infections: pathogenesis and vaccine development. Pathogens. 2021;10:119.","journal-title":"Pathogens"},{"key":"942_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105647","volume":"169","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wan R, Yuan Q, Dou H, Tu P, Shi D, et al. Cell damage and neutrophils promote the infection of Mycoplasma pneumoniae and inflammatory response. Micro Pathog. 2022;169:105647.","journal-title":"Micro Pathog"},{"key":"942_CR20","doi-asserted-by":"publisher","unstructured":"Moreira W, Ngan GJ, Low JL, Poulsen A, Chia BC, Ang MJ et al. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria. MBio. 2015; 6: https:\/\/doi.org\/10.1128\/mbio.00253-00215.","DOI":"10.1128\/mbio.00253-00215"},{"key":"942_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58410-4","volume":"16","author":"B Zhou","year":"2025","unstructured":"Zhou B, Gao Y, Zhao H, Liu B, Zhang H, Fang C, et al. Structural insights into bortezomib-induced activation of the caseinolytic chaperone-protease system in Mycobacterium tuberculosis. Nat Commun. 2025;16:3466.","journal-title":"Nat Commun"},{"key":"942_CR22","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071\u20136.","journal-title":"Cancer Res"},{"key":"942_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1042\/BST0360781","volume":"36","author":"G Marfany","year":"2008","unstructured":"Marfany G, Farras R, Salido E, Xirodimas DP, Rodr\u00edguez MS. Much to know about proteolysis: intricate proteolytic machineries compromise essential cellular functions. Biochem Soc Trans. 2008;36:781\u20135.","journal-title":"Biochem Soc Trans"},{"key":"942_CR24","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/oby.21081","volume":"23","author":"LM Bollinger","year":"2015","unstructured":"Bollinger LM, Powell JJ, Houmard JA, Witczak CA, Brault JJ. Skeletal muscle myotubes in severe obesity exhibit altered ubiquitin-proteasome and autophagic\/lysosomal proteolytic flux. Obesity. 2015;23:1185\u201393.","journal-title":"Obesity"},{"key":"942_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2021.5026","volume":"48","author":"L Hu","year":"2021","unstructured":"Hu L, Pan X, Hu J, Zeng H, Liu X, Jiang M, Jiang B. Proteasome inhibitors decrease paclitaxel\u2011induced cell death in nasopharyngeal carcinoma with the accumulation of CDK1\/cyclin B1. Int J Mol Med. 2021;48:1\u201311.","journal-title":"Int J Mol Med"},{"key":"942_CR26","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20209530","volume":"16","author":"R Burgos","year":"2020","unstructured":"Burgos R, Weber M, Martinez S, Lluch-Senar M, Serrano L. Protein quality control and regulated proteolysis in the genome-reduced organism Mycoplasma pneumoniae. Mol Syst Biol. 2020;16:MSB20209530.","journal-title":"Mol Syst Biol"},{"key":"942_CR27","first-page":"1008","volume":"41","author":"K-H Lee","year":"2018","unstructured":"Lee K-H, Lee J, Woo J, Lee C-H, Yoo C-G. Proteasome inhibitor-induced I\u03baB\/NF-\u03baB activation is mediated by Nrf2-dependent light chain 3B induction in lung cancer cells. Mol Cells. 2018;41:1008\u201315.","journal-title":"Mol Cells"},{"key":"942_CR28","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.4049\/jimmunol.164.8.4292","volume":"164","author":"S Schoonbroodt","year":"2000","unstructured":"Schoonbroodt S, Ferreira VR, Best-Belpomme M, Boelaert JR, Legrand-Poels S, Korner M, Piette J. Crucial role of the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I\u03baB\u03b1 in NF-\u03baB activation by an oxidative stress. J Immunol. 2000;164:4292\u20134300.","journal-title":"J Immunol"},{"key":"942_CR29","doi-asserted-by":"publisher","first-page":"e52969","DOI":"10.1371\/journal.pone.0052969","volume":"7","author":"D Jiang","year":"2012","unstructured":"Jiang D, Nelson ML, Gally F, Smith S, Wu Q, Minor M, et al. Airway epithelial NF-\u03baB activation promotes Mycoplasma pneumoniae clearance in mice. PLoS One. 2012;7:e52969.","journal-title":"PLoS One"},{"key":"942_CR30","doi-asserted-by":"crossref","unstructured":"Yang, Y., Ikezoe, T., Saito, T., Kobayashi, M., Koeffler, H.P. and Taguchi, H.Proteasome inhibitor PS\u2010341 induces growth arrest and apoptosis of non\u2010small cell lung cancer cells via the JNK\/c\u2010Jun\/AP\u20101 signaling. Cancer science, 2004;95:176\u201380.","DOI":"10.1111\/j.1349-7006.2004.tb03200.x"},{"key":"942_CR31","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1002\/ptr.7875","volume":"37","author":"X Su","year":"2023","unstructured":"Su X, Guo H, Zhou Y, Cao A, Shen Q, Zhu B, et al. Astragaloside IV attenuates high glucose-induced NF-\u03baB-mediated inflammation through activation of PI3K\/AKT-ERK-dependent Nrf2\/ARE signaling pathway in glomerular mesangial cells. Phytother Res. 2023;37:4133\u201348.","journal-title":"Phytother Res"},{"key":"942_CR32","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41419-022-05495-0","volume":"13","author":"F Favaro","year":"2022","unstructured":"Favaro F, Luciano-Mateo F, Moreno-Caceres J, Hern\u00e1ndez-Madrigal M, Both D, Montironi C, et al. TRAIL receptors promote constitutive and inducible IL-8 secretion in non-small cell lung carcinoma. Cell Death Dis. 2022;13:1046.","journal-title":"Cell Death Dis"},{"key":"942_CR33","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/ppul.26593","volume":"58","author":"XQ Luo","year":"2023","unstructured":"Luo XQ, Luo J, Wang CJ, Luo ZX, Tian DY, Xie XH. Clinical features of severe Mycoplasma pneumoniae pneumonia with pulmonary complications in childhood: a retrospective study. Pediatr Pulmonol. 2023;58:2815\u201322.","journal-title":"Pediatr Pulmonol"},{"key":"942_CR34","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/jcm10061154","volume":"10","author":"E Lee","year":"2021","unstructured":"Lee E, Lee YY. Predictive factors of the responses to treatment of Mycoplasma pneumoniae pneumonia. J Clin Med. 2021;10:1154.","journal-title":"J Clin Med"},{"key":"942_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jmii.2020.03.030","volume":"54","author":"Y-C Lee","year":"2021","unstructured":"Lee Y-C, Chang C-H, Lee W-J, Liu T-Y, Tsai C-M, Tsai T-A, et al. Altered chemokine profile in refractory Mycoplasma pneumoniae pneumonia infected children. J Microbiol, Immunol Infect. 2021;54:673\u20139.","journal-title":"J Microbiol, Immunol Infect"},{"key":"942_CR36","doi-asserted-by":"publisher","first-page":"e50523","DOI":"10.1371\/journal.pone.0050523","volume":"7","author":"E Eriksson","year":"2012","unstructured":"Eriksson E, Zaman F, Chrysis D, Wehtje H, Heino TJ, S\u00e4vendahl L. Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. PLoS One. 2012;7:e50523.","journal-title":"PLoS One"},{"key":"942_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/jcsm.12050","volume":"7","author":"F Penna","year":"2016","unstructured":"Penna F, Bonetto A, Aversa Z, Minero VG, Rossi Fanelli F, Costelli P, Muscaritoli M. Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J Cachexia Sarcopenia Muscle. 2016;7:345\u201354.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"942_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.trim.2013.09.010","volume":"29","author":"R Redfield","year":"2013","unstructured":"Redfield R, Lou Y, Rodriguez E, Rostami S, Parsons R, Noorchashm H, et al. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice. Transpl Immunol. 2013;29:11\u201316.","journal-title":"Transpl Immunol"},{"key":"942_CR39","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander T, Sarfert R, Klotsche J, K\u00fchl AA, Rubbert-Roth A, Lorenz H-M, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1474\u20138.","journal-title":"Ann Rheum Dis"},{"key":"942_CR40","doi-asserted-by":"crossref","unstructured":"Ding GD, Zhang XB, Vinturache A, van Rossum AMC, Yin Y, Zhang YJ. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Eur J Pediatr. 2024;183:3001\u201311.","DOI":"10.1007\/s00431-024-05519-1"},{"key":"942_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fmicb.2016.00039","volume":"7","author":"R Dumke","year":"2016","unstructured":"Dumke R, Jacobs E. Antibody response to Mycoplasma pneumoniae: protection of host and influence on outbreaks? Front Microbiol. 2016;7:39.","journal-title":"Front Microbiol"},{"key":"942_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6343818","volume":"2022","author":"D Poddighe","year":"2022","unstructured":"Poddighe D, Demirkaya E, Sazonov V, Romano M. Mycoplasma pneumoniae infections and primary immune deficiencies. Int J Clin Pract. 2022;2022:6343818.","journal-title":"Int J Clin Pract"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00942-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:03:39Z","timestamp":1790546619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00942-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1038\/s41429-026-00942-y","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The animal experiment procedure was approved by the Experimental Animal Ethics Committee of Southwest Medical University (20240305-042).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}